Gludantan – (12707-95-8)

Gludantan, also known as gludantane, is an experimental antiparkinsonian agent of the adamantane group that was never marketed. It was developed in the Soviet Union and first described in 1974.

Gludantan has been described as a psychotropic and antidepressant. An analogue of gludantan, N-3,5-dimethylgludantan, is an inactive metabolite of memantine.

The drug demonstrated higher antiparkinsonian activity compared to cholinolytic preparations and midantane, particularly in rigid and rigid-trembling forms of parkinsonism, but was less effective in trembling-rigid forms and ineffective in the trembling form.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Gludantan
https://pubmed.ncbi.nlm.nih.gov/1217399/